A deal for exclusive global rights to a hypoxia inducible factor-prolyl hydroxylase (HIF-PH) inhibitor developed by Japanese firm Taisho Pharmaceutical Co. Ltd. has given private US venture BioAge its first clinical-stage asset, which it intends to develop for multiple diseases of aging.
Characterizing the agreement as a “significant milestone”, Richmond, CA-based BioAge will make undisclosed upfront, development and commercial milestone payments based...





![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)
